One stock that might be an intriguing choice for investors right now is Glu Mobile Inc. (NASDAQ:GLUU). This is because this security in the Multimedia & Graphics Software space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Multimedia & Graphics Software space as it currently has a Zacks Industry Rank of 48 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there. Glu Mobile Inc. (NASDAQ:GLUU) shares after opening at $4.49 moved to $4.55 on last trade day and at the end of the day closed at $4.18. Company price to sales ratio in past twelve months was calculated as 3.19 and price to cash ratio as 11.81. Glu Mobile Inc. (NASDAQ:GLUU) showed a negative weekly performance of -7.11%.
Piper Jaffray downgrades VIVUS, Inc. (Nasdaq:VVUS) from Neutral to Underweight on Thursday, while slashing its price target from $8 down to $3.VIVUS, Inc. (NASDAQ:VVUS) shares fell -6.55% in last trading session and ended the day on $5.42. VVUS return on equity ratio is recorded as -104.50% and its return on assets is -46.80%. VIVUS, Inc. (NASDAQ:VVUS) yearly performance is -48.03%.
Sonus Networks, Inc. (Nasdaq: SONS), a global leader in SIP communications announced that it will report financial results for the first quarter of 2014 before the open of the market on Thursday, April 24, 2014. Following the release, Sonus will host a conference call with the financial community at 8:30 a.m. ET to discuss the results.Sonus Networks, Inc. (NASDAQ:SONS) shares moved down -6.38% in last trading session and was closed at $3.23, while trading in range of $3.23-$3.49. Sonus Networks, Inc. (NASDAQ:SONS) year to date performance is 2.54%.
ACADIA Pharmaceuticals (NASDAQ:ACAD) Director Torsten Rasmussen unloaded 30,000 shares of the stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $21.98, for a total value of $659,400.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) weekly performance is -5.74%. On last trading day company shares ended up $21.35. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) distance from 50-day simple moving average is -16.40%. Analysts mean target price for the company is $31.50.